Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for patients with Parkinson’s disease and motor fluctuations: Results from the Phase 3 randomized, active-controlled BouNDless study
Objective: Determine the efficacy, safety, and tolerability of ND0612 versus oral immediate-release levodopa/carbidopa (IR-LD/CD) in people with Parkinson’s disease (PwP) experiencing motor fluctuations. Background: ND0612…Dietary protein redistribution influences the efficacy of levodopa/carbidopa intestinal gel (LCIG) infusion
Objective: To compare levodopa/carbidopa intestinal gel (LCIG) with equally distributed dietary protein (Diet_EDP) versus restricted to twice daily (Diet_RP) and Mediterranean diet (Diet_M). Background: Levodopa…Rapid onset of good ON time and improvement in motor-state stability in aPD patients after treatment with continuous subcutaneous foslevodopa/foscarbidopa
Objective: To evaluate time to ON without troublesome dyskinesia (‘good ON’) and patterns of motor-state stability throughout the day in patients with advanced Parkinson’s disease…Assessment of microstructural changes associated with levodopa-induced dyskinesia in hemiparkinsonian rodents
Objective: To assess white matter (WM) microstructural integrity changes in pre-clinical models of Parkinson’s disease (PD) with levodopa-induced dyskinesia (LID). Background: PD is a neurodegenerative…Nutritional Status in Advanced Parkinson’s Disease: Preliminary Results.
Objective: To analyze the relationship between nutritional intake and weight aspects in 3 groups of patients with Parkinson's disease (PD) who are receiving different pharmacological…Use of a wearable medical device for LCIG tube adjustment: a user case
Objective: To identify objectively the change in motor symptoms in a patient with Parkinson’s Disease (PD) on levodopa-carbidopa intestinal gel (LCIG) treatment with and without…Dopamine agonist utilization prior to the initiation of device aided therapy: data from 150 patients with advanced Parkinson’s disease treated with Levodopa Carbidopa Intestinal Gel
Objective: Objective: To evaluate the usage of dopamine agonists (DA) as part of the last conventional dopaminergic treatment in a large cohort of consecutive patients…Impact of foslevodopa/foscarbidopa on key clinical and patient-reported outcomes in patients with aPD: Responder analysis of two Phase 3 clinical trials
Objective: To evaluate the effect of foslevodopa/foscarbidopa (LDP/CDP, ABBV-951) on clinical and patient-reported outcomes in advanced Parkinson’s disease (aPD) patients using minimal clinically important difference…Effect of freezing of gait and antiparkinsonian medication on joint kinematics and kinetics in gait in patients with Parkinson’s disease
Objective: This study aims to evaluate the interaction between FoG and antiparkinsonian medication on individuals with PD's kinematic and kinetic gait parameters. Background: Regarding Parkinson's…DIFFERENT PATTERNS OF ACUTE SACCADIC RESPONSES TO LEVODOPA CHALLENGE TEST IN DE NOVO PARKINSON’S DISEASE: POSSIBILE PROGNOSTIC IMPLICATIONS
Objective: To explore possible different patterns of acute saccadic responses to Levodopa Challenge Test (LCT) in a de novo drug-naïve Parkinson’s Disease (PD) population and…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 70
- Next Page »